By MIKE STOBBE

NEW YORK (AP) — Researchers on Wednesday reported two promising new approaches to counteract malaria’s growing resistance to medication — one involving a new class of drugs.

Related Articles

Switzerland-based Novartis released results of what it called a next-generation treatment. A study of its experimental drug in 12 African countries found it works well against the mosquito-borne parasite that causes malaria and seems to block spread.

The drug, called GanLum, is not yet licensed and more than a year away from being available.

It’s needed, said Dr. David Sullivan, a malaria expert at Johns Hopkins University.

The parasite that causes the disease is developing resistance to existing drugs, meaning “the ice is thinning,” Sullivan said. “It hasn’t given way, but we’re c

See Full Page